Clinical Data GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints BioSpaceOver the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: April 30, 2026) BioSpace Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Norgine gets first EU approval for WHIM syndrome therapyNext: AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio Related Stories Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study pharminent May 26, 2026 Clinical Data Parkinson’s drug from Biogen, Denali comes up short pharminent May 22, 2026 Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026
